Table 5.

Summary of dichotomous outcomes for sildenafil

		Number of		Percent with
Outcome	Dose (mg)	Trials	Patients	Sildenafil	Placebo	Relative benefit or risk (95% CI)	NNT/NNTp/NNH (95% CI)
Efficacy
Improved erections	25	5	778	68	27	2.5 (2.1 to 3.0)	2.4 (2.1 to 2.9)
	50	5	781	80	27	3.0 (2.5 to 3.5)	1.9 (1.7 to 2.1)
	100	26	5000	76	23	3.4 (3.1 to 3.6)	1.9 (1.8 to 2.0)
	50/100	29	5467	76	23	3.3 (3.1 to 3.5)	1.9 (1.8 to 2.0)
Withdrawal
All-cause	25	3	522	11	14	0.9 (0.6 to 1.4)	not calculated
	50	4	560	10	14	0.7 (0.4 to 1.2)	not calculated
	100	27	5219	7.8	12	0.6 (0.5 to 0.8)	22 (16 to 34)
	50/100	30	5562	8.0	12	0.7 (0.6 to 0.8)	23 (17 to 37)
Lack of efficacy	25	3	522	3.0	3.7	0.9 (0.3 to 2.5)	not calculated
	50	3	526	1.8	3.5	0.6 (0.2 to 1.9)	not calculated
	100	27	5119	1.1	4.5	0.3 (0.2 to 0.4)	24 (20 to 32)
	50/100	30	5463	1.2	4.4	0.3 (0.2 to 0.4)	25 (21 to 34)
Adverse event	25	4	777	1.5	1.3	1.0 (0.4 to 3.0)	not calculated
	50	5	819	1.6	1.2	1.7 (0.7 to 4.4)	not calculated
	100	28	5311	1.4	0.6	1.8 (1.1 to 2.7)	120 (66 to 520)
	50/100	31	5787	1.6	0.6	1.7 (1.1 to 2.6)	120 (67 to 560)
Adverse events
All cause	50/100	18	2852	50	30	1.6 (1.5 to 1.8)	4.9 (4.2 to 6.0)
Serious	50/100	17	2591	2.5	2.4	1.1 (0.6 to 1.7)	not calculated
Headache	50/100	34	6386	17	5.2	3.3 (2.8 to 3.9)	8.6 (7.6 to 10)
Dyspepsia	50/100	26	4967	7.8	2.3	3.3 (2.5 to 4.4)	18 (15 to 23)
Flushing	50/100	33	6363	13	1.9	6.7 (5.2 to 8.7)	9.0 (8.1 to 10)
Rhinitis	50/100	21	4283	5.4	2.1	2.5 (1.8 to 3.5)	31 (23 to 47)

NNT is given in standard font, NNTp in bold, and NNH in bold italic. No NNT/NNTp/NNH was calculated unless there was a statistically significant difference